US FDA chief: We are not targeting Indian companies
This article was originally published in SRA
The US Food and Drug Administration has increased its presence in India apparently does not mean US regulators are scrutinizing drug makers in that country to any greater extent than the agency does elsewhere.
You may also be interested in...
Not all technology platforms provide the expected benefit of filling in CMC review gaps and speeding coronavirus vaccine approvals.
A long-term, patient-centric group of investors is backing SparingVision's bid to develop a gene therapy treatment for retinitis pigmentosa that could be effective regardless of mutation.
“There’s a heightened need for products that deliver against health, hygiene and clean home concerns and a willingness to spend just a little bit more to ensure that I’m using a product that I know and trust,” says CFO Jon Moeller